利培酮与奥氮平对精神分裂症患者的疗效及生活质量影响的对照研究(1)
[摘要] 目的 比较利培酮与奥氮平对精神分裂症患者的疗效及生活质量的影响。 方法 对2013年1月～2014年12月68例精神分裂症患者，随机分为利培酮组(34例)与奥氮平组(34例)治疗，疗程12周。采用副反应用量表(TESS)、阳性与阴性症状量表(PANSS)及生活质量综合评定问卷(GQOLI-74)评定两组患者治疗第4周、8周和12周末的不良反应、临床效果以及生活质量。 结果 两组患者治疗后PANSS总分及各因子分较治疗前显著降低(P<0.05)，两组间各时点的总分及各因子分无显著性差异(P>0.05)；通过PANSS比较说明两组治疗效果差异不大；奥氮平组不良反应发生率(33.3%)与利培酮组不良反应发生率(30.0%)比较，差异无统计学意义(P>0.05)。利培酮组主要的不良反应泌乳素水平增高、月经紊乱和停经、锥体外系反应明显高于奥氮平组(P<0.05)，利培酮组在体重增加、嗜睡和血糖升高方面明显低于奥氮平组(P<0.05)；治疗前两组GQOLI-74总分及各因子分差异无统计学意义(P>0.05)；治疗12周后，除了物质生活维度外，两组生活质量总分以及各个因子分显著提高，差异有统计学意义(P<0.05)，而物质生活维度评分治疗前后无明显改善(P>0.05)，治疗后，两组间比较也无显著性差异(P>0.05)。 结论 利培酮与奥氮平对精神分裂症疗效好，不良反应少，均可提高生活质量。
[关键词] 利培酮；奥氮平；精神分裂症；PANSS；生活质量
[中图分类号] R914 [文献标识码] B [文章编号] 1673-9701(2016)21-0107-04
[Abstract] Objective To investigate the efficacy and quality of life of schizophrenic patients treated by risperidon and olanzapine. Methods A total of 68 cases of patients with schizophrenia from Jan 2013 to Dec 2014 were randomly divided into Risperidon group and olanzapine group for 12-week treatment. After treated for 4 weeks， 8 weeks and 12 weeks，the clinical efficacy、adverse reactions and the quality of life were evaluated by Positive and Negative Symptoms Scale(PANSS)， Treatment Emergent Symptom Scal(TESS) and General Quality of Life Inventory(GQOLI-74). Results After treatment， the PANSS score and factor score decreased significantly than before treatment(P<0.05)， the total points and factor scores at each time point between the two groups showed no significant difference(P>0.05)， the PANSS comparison illustrated the effects of treatment showed no significant difference； The incidence of adverse reactions(33.3%) of olanzapine group and incidence of adverse reactions(30.0%) of risperidone group showed no significant difference(P>0.05). The major adverse reactions increased prolactin levels，menstrual disorders and menopause，extrapyramidal symptoms of risperidone group were significantly higher than olanzapine group(P<0.05)，the changes of weight gain，lethargy and elevated blood glucose aspects of risperidone group were significantly lower than olanzapine group(P<0.05)； the GQOLI-74 total score and factor score before treatment between the two groups showed no significant difference(P>0.05)； Excepted the material dimension of lief， the quality of life scores and the various factor scores after 12 weeks of treatment of the two groups significantly increased，the differences were statistically significant，but the material dimension of life before and after treatment showed no significant improvement(P>0.05)，after treatment，the two groups also showed no significant difference(P>0.05). Conclusion Risperidon and olanzapine are similar in the treatment of schizophrenia with fewer side effects，and they both can improve quality of life., 百拇医药(金枝 罗继明 王鹤秋)
[关键词] 利培酮；奥氮平；精神分裂症；PANSS；生活质量
[中图分类号] R914 [文献标识码] B [文章编号] 1673-9701(2016)21-0107-04
[Abstract] Objective To investigate the efficacy and quality of life of schizophrenic patients treated by risperidon and olanzapine. Methods A total of 68 cases of patients with schizophrenia from Jan 2013 to Dec 2014 were randomly divided into Risperidon group and olanzapine group for 12-week treatment. After treated for 4 weeks， 8 weeks and 12 weeks，the clinical efficacy、adverse reactions and the quality of life were evaluated by Positive and Negative Symptoms Scale(PANSS)， Treatment Emergent Symptom Scal(TESS) and General Quality of Life Inventory(GQOLI-74). Results After treatment， the PANSS score and factor score decreased significantly than before treatment(P<0.05)， the total points and factor scores at each time point between the two groups showed no significant difference(P>0.05)， the PANSS comparison illustrated the effects of treatment showed no significant difference； The incidence of adverse reactions(33.3%) of olanzapine group and incidence of adverse reactions(30.0%) of risperidone group showed no significant difference(P>0.05). The major adverse reactions increased prolactin levels，menstrual disorders and menopause，extrapyramidal symptoms of risperidone group were significantly higher than olanzapine group(P<0.05)，the changes of weight gain，lethargy and elevated blood glucose aspects of risperidone group were significantly lower than olanzapine group(P<0.05)； the GQOLI-74 total score and factor score before treatment between the two groups showed no significant difference(P>0.05)； Excepted the material dimension of lief， the quality of life scores and the various factor scores after 12 weeks of treatment of the two groups significantly increased，the differences were statistically significant，but the material dimension of life before and after treatment showed no significant improvement(P>0.05)，after treatment，the two groups also showed no significant difference(P>0.05). Conclusion Risperidon and olanzapine are similar in the treatment of schizophrenia with fewer side effects，and they both can improve quality of life., 百拇医药(金枝 罗继明 王鹤秋)